Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA2B | P29275 | 4/20 | 0.39 |
| ▸ | ADORA2A | P29274 | 3/20 | 0.39 |
| ▸ | ADORA3 | P0DMS8 | 2/20 | 0.39 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.37 |
| ▸ | LMNA | P02545 | 2/20 | 0.37 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.37 |
| ▸ | MAPT | P10636 | 1/20 | 0.37 |
| ▸ | TSHR | P16473 | 1/20 | 0.37 |
| ▸ | BLM | P54132 | 1/20 | 0.37 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.37 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.36 |
| ▸ | ADRA1D | P25100 | 1/20 | 0.36 |
| ▸ | HTR1E | P28566 | 1/20 | 0.36 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.36 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.36 |
| ▸ | ADRA1B | P35368 | 1/20 | 0.36 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.36 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.36 |
| ▸ | APAF1 | O14727 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8696414 | 0.79 | TYMP (0.41) | ADORA2BADORA2AADORA3ADORA1ALDH1A1 | |
| SCHEMBL27384925 | 0.77 | ADORA2B (0.37) | ADORA2BADORA2AADORA3ADORA1ALDH1A1 | |
| SCHEMBL28143896 | 0.77 | TYMP (0.40) | ADORA2BADORA2AADORA3ADORA1ALDH1A1 | |
| SCHEMBL10178080 | 0.77 | CSNK2A2 (0.44) | ADORA2BADORA2AADORA3ADORA1ALDH1A1 | |
| SCHEMBL25980042 | 0.77 | TYMP (0.40) | ADORA2BADORA2AADORA3ADORA1ALDH1A1 | |
| SCHEMBL24097424 | 0.77 | ADORA2B (0.37) | ADORA2BADORA2AADORA3ADORA1ALDH1A1 | |
| SCHEMBL10279639 | 0.77 | ADORA2B (0.37) | ADORA2BADORA2AADORA3ADORA1ALDH1A1 | |
| SCHEMBL2272851 | 0.74 | ALDH1A1 (0.39) | ADORA2BADORA2AADORA3ADORA1ALDH1A1 | |
| SCHEMBL1946777 | 0.74 | ALDH1A1 (0.50) | ADORA2BADORA2AADORA3ADORA1ALDH1A1 | |
| SCHEMBL17582661 | 0.74 | SMN1; SMN2 (0.43) | ADORA2BADORA2AADORA3ADORA1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 101 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1413286-B1 | Dyeing composition comprising at least one heterocyclic oxidation base and at least one substituted 2,3-diaminopyridine as a coupling agent | OREAL (FR) | 2009-04-22 | — | — | EP | claimed |
| WO-2007071688-A1 | COMPOSITION FOR DYEING KERATIN FIBRES WITH A TETRAAZAPENTAMETHINE CATIONIC DIRECT DYE, A PARTICULAR OXIDATION BASE AND A COUPLER | L'ORÉAL (FR) | 2007-06-28 | — | — | WO | claimed |
| US-20250034143-A1 | SUBSTITUTED XANTHINES AND METHODS OF USE THEREOF | HYDRA BIOSCIENCES, LLC (US) | 2025-01-30 | — | — | US | disclosed |
| US-11958854-B2 | Substituted xanthines and methods of use thereof | HYDRA BIOSCIENCES, LLC (US) | 2024-04-16 | — | — | US | disclosed |
| US-11772085-B2 | Far superior oxidation catalysts based on macrocyclic compounds | CARNEGIE MELLON UNIVERSITY (US) | 2023-10-03 | — | — | US | disclosed |
| US-20230226065-A1 | ANTI-INFLAMMATORY COMPOSITIONS, METHODS AND USES THEREOF | COMVITA LIMITED (NZ) | 2023-07-20 | — | — | US | disclosed |
| US-20230226065-A1 | ANTI-INFLAMMATORY COMPOSITIONS, METHODS AND USES THEREOF | COMVITA LIMITED (NZ) | 2023-07-20 | — | — | US | disclosed |
| US-20230226065-A1 | ANTI-INFLAMMATORY COMPOSITIONS, METHODS AND USES THEREOF | COMVITA LIMITED (NZ) | 2023-07-20 | — | — | US | disclosed |
| EP-4175641-A1 | ANTI-INFLAMMATORY COMPOSITIONS, METHODS AND USES THEREOF | Comvita Limited (NZ) | 2023-05-10 | — | — | EP | disclosed |
| US-20230040259-A1 | SUBSTITUTED XANTHINES AND METHODS OF USE THEREOF | HYDRA BIOSCIENCES, LLC (US) | 2023-02-09 | — | — | US | disclosed |
| US-20230040259-A1 | SUBSTITUTED XANTHINES AND METHODS OF USE THEREOF | HYDRA BIOSCIENCES, LLC (US) | 2023-02-09 | — | — | US | disclosed |
| WO-2004104005-A2 | IMMUNOSUPPRESSIVE EFFECTS OF PTERIDINE DERIVATIVES | 4 AZA BIOSCIENCE NV (BE) | 2004-12-02 | — | — | WO | disclosed |
| US-6825349-B2 | PURINE DERIVATIVES FOR TREATMENT OF GASTROINTESTINAL DISORDERS, IMMUNOLOGICAL DISORDERS, NEUROLOGICAL DISORDERS | CV THERAPEUTICS INC. | 2004-11-30 | — | — | US | disclosed |
| EP-1479682-A1 | Immunosuppressive effects of pteridine derivatives | 4 AZA Bioscience nv (BE) | 2004-11-24 | — | — | EP | disclosed |
| EP-1444233-A2 | A 2B? ADENOSINE RECEPTOR ANTAGONISTS | CV THERAPEUTICS, INC. (US) | 2004-08-11 | — | — | EP | disclosed |
| US-20030229106-A1 | A2B adenosine receptor antagonists | GILEAD SCIENCES, INC. | 2003-12-11 | — | — | US | disclosed |
| US-20030139428-A1 | A2B adenosine receptor antagonists | GILEAD SCIENCES, INC. | 2003-07-24 | — | — | US | disclosed |
| WO-2003042214-A2 | A2B ADENOSINE RECEPTOR ANTAGONISTS | CV THERAPEUTICS, INC. (US) | 2003-05-22 | — | — | WO | disclosed |
| EP-0914206-A1 | LONG-LIVED HOMOGENOUS OXIDATION CATALYSTS | CARNEGIE-MELLON UNIVERSITY (US) | 1999-05-12 | — | — | EP | disclosed |
| WO-1998003263-A1 | LONG-LIVED HOMOGENOUS OXIDATION CATALYSTS | CARNEGIE MELLON UNIVERSITY (US) | 1998-01-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230226065-A1 | ANTI-INFLAMMATORY COMPOSITIONS, METHODS AND USES THEREOF | PTGES2, TPMT, PARK7 | ADORA2B 3151/4885ADORA2A 2457/4885ADORA3 3733/4885 |
| US-11772085-B2 | Far superior oxidation catalysts based on macrocyclic compounds | SOD1, ME3, ME2 | ADORA2B 2335/4885ADORA2A 2532/4885ADORA3 1536/4885 |
| US-20030139428-A1 | A2B adenosine receptor antagonists | ADORA2B, ADORA2A, ADORA1 | ADORA2B 1/4885ADORA2A 2/4885ADORA3 4/4885 |
| US-20030229106-A1 | A2B adenosine receptor antagonists | ADORA2B, ADORA2A, ADORA1 | ADORA2B 1/4885ADORA2A 2/4885ADORA3 4/4885 |
| US-11958854-B2 | Substituted xanthines and methods of use thereof | TRPC5, TRPC7, TRPC4 | ADORA2B 577/4885ADORA2A 486/4885ADORA3 449/4885 |
| US-20230040259-A1 | SUBSTITUTED XANTHINES AND METHODS OF USE THEREOF | TRPC5, TRPC7, TRPC4 | ADORA2B 577/4885ADORA2A 486/4885ADORA3 449/4885 |
| US-20250034143-A1 | SUBSTITUTED XANTHINES AND METHODS OF USE THEREOF | TRPC5, TRPC7, TRPC4 | ADORA2B 577/4885ADORA2A 486/4885ADORA3 449/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.